About Us

Our Mission

What We Do

Osivax is a clinical-stage biotechnology company developing a transformative pipeline of universal vaccines uniquely designed to leverage both arms of the immune system: superior T-cell immune responses generated by its proprietary oligoDOM® technology, and B-cell responses brought by conventional vaccines. Osivax’ mission is to develop universal vaccine candidates designed to provide protection against viruses that mutate rapidly, starting with influenza and rapidly expanding to other areas such as Covid-19, HPV….

Since 2017

Founded in 2017, Osivax’ management team consists of experienced multi-disciplinary professionals committed to executing on the platform’s potential and who are supported by premier scientific and clinical advisory boards. Since 2017, Osivax’ team has developed its universal influenza vaccine from preclinical stage to phase 2 trials with over 800 subjects recruited so far and several proofs of concept generated on the platform technology.

Our Locations

Osivax is based in Lyon, France and Liège, Belgium, two of the premier vaccine R&D clusters in Europe. Osivax recently incorporated an affiliate in Australia to oversee local clinical trials.

Our Team

Alexandre Le Vert

Executive Chairman & Co-Founder

Dr Florence Nicolas, PhD

Chief Development Officer & Co-Founder

Dr Paul Willems, MD

Chief Medical Officer

Dr. Delphine Guyon-Gellin, DVM

Chief Business Development Officer

Linda Lebon

Chief Regulatory Officer

Jessika Tourneur

Clinical Development Director

Vincent Bille, PhD

Chief Manufacturing Officer

Florian Sourd

VP Finance

Prof. Jeffrey Almond, PhD

Chairman of the Scientific Advisory Board

Dr Nathalie Garcon, Pharm D, PhD

Member of the Scientific Advisory Board

Dr Fergal Hill, MD

Member of the Scientific Advisory Board & Co-Founder

Dr. Tim Mosmann

Member of the Scientific Advisory Board

Prof. Sir Andrew J McMichael

Member of the Scientific Advisory Board

Prof. Geert Leroux-Roels, MD, PhD

Member of the clinical Advisory Board

Dr Bernard Fritzell, MD

Member of the clinical Advisory Board

Dr W. Ripley Ballou, MD

Member of the clinical Advisory Board

Prof. Odile Launay, MD, PhD

Member of the clinical Advisory Board

Prof. Pierre Vandamme, MD, PhD

Member of the clinical Advisory Board

Alexandre Le Vert

Executive Chairman & Co-Founder

Dr Michael Watson, MD

Former President of Moderna Vaccine Division, Current CEO of VaxEquity

Frédéric Schynts, PhD

Noshaq Investment Manager

Dr Christian Pradeyrol, MD

Executive Chairman and founder of Pradeyrol Développement

Dr Thomas Joudinaud, MD

CEO of Ceres-Brain Therapeutics

Alexandre Heraud

Anaxago Investment Director

Our Investors

Osivax’ approach and mission are further validated and supported by our trusted investors.

Our Partners

We are working on transforming the high-value vaccine development landscape through our game-changing oligoDOM® technology platform and the universal vaccine candidates in our proprietary pipeline. Our platform supports multiple collaboration and licensing opportunities for optimizing or enabling other vaccine technologies. We participate in strategic partnerships with other leaders in the infectious disease and vaccinology space to support our efforts.